Cargando…

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond

Blockade of the programmed death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) receptor axis represents an effective form of cancer immunotherapy. Preclinical evidence initially suggested that gastric and gastroesophageal junction (GEJ) cancers are potentially immunotherapy-sensitive tumors. E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Emily M, Gong, Jun, Klempner, Samuel J, Chao, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034145/ https://www.ncbi.nlm.nih.gov/pubmed/29991874 http://dx.doi.org/10.3748/wjg.v24.i25.2686

Ejemplares similares

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer
por: Maeda, Osamu, et al.
Publicado: (2019)

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
por: Homet Moreno, B, et al.
Publicado: (2015)

Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
por: Zheng, Lin-Lin, et al.
Publicado: (2021)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
por: Cho, Junhun, et al.
Publicado: (2017)

Focus on gastroesophageal reflux disease in patients with cystic fibrosis
por: Bongiovanni, Annarita, et al.
Publicado: (2020)

Endoscopic anti-reflux therapy for gastroesophageal reflux disease
por: Rodríguez de Santiago, Enrique, et al.
Publicado: (2021)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Risk factors for gastroesophageal reflux disease and analysis of genetic contributors
por: Argyrou, Alexandra, et al.
Publicado: (2018)

Proposed approach to the challenging management of progressive gastroesophageal reflux disease
por: Labenz, Joachim, et al.
Publicado: (2018)

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017)

Microvasculature of the esophagus and gastroesophageal junction: Lesson learned from submucosal endoscopy
por: Maselli, Roberta, et al.
Publicado: (2016)

Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications
por: Fu, Ruisi, et al.
Publicado: (2018)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
por: Yu, Hung-Yuan, et al.
Publicado: (2022)

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
por: Ha, Hyerim, et al.
Publicado: (2019)

Management of gastroesophageal reflux disease: Patient and physician communication challenges and shared decision making
por: Klenzak, Scott, et al.
Publicado: (2018)

Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer
por: Watson, M M C, et al.
Publicado: (2014)

Leveraging NKG2D Ligands in Immuno-Oncology
por: Fuertes, Mercedes Beatriz, et al.
Publicado: (2021)

PD‐L1 and beyond: Immuno‐oncology in cytopathology
por: Iaccarino, Antonino, et al.
Publicado: (2021)

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
por: Gerard, C., et al.
Publicado: (2023)

Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status
por: Nestarenkaite, Ausrine, et al.
Publicado: (2020)

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
por: Randrian, Violaine, et al.
Publicado: (2021)

Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force
por: Butterfield, Lisa H, et al.
Publicado: (2010)

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

Inducing immunogenic cell death in immuno-oncological therapies
por: Ti, Dongdong, et al.
Publicado: (2022)

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Beyond the Hox complex
por: Patel, Nipam H, et al.
Publicado: (2000)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations
por: Sfakianaki, Maria, et al.
Publicado: (2023)

Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability
por: Montella, Marco, et al.
Publicado: (2022)

Clinical infections in neurosurgical oncology: An overview
por: Velnar, Tomaz, et al.
Publicado: (2023)

Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
por: Hou, Yong-Zhe, et al.
Publicado: (2023)

Editorial: Microsatellite and microsatellite instability
por: How-Kit, Alexandre, et al.
Publicado: (2023)

Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
por: Cesano, Alessandra, et al.
Publicado: (2018)

Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer
por: Lee, Belinda, et al.
Publicado: (2019)

Immune landscape and biomarkers for immuno-oncology in colorectal cancers
por: Bae, Jeong Mo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_umsulja5m1m75omn82v153r39h